PDF herunterladen
CC BY-NC-ND 4.0 · J Neuroanaesth Crit Care 2020; 7(03): 140-147
DOI: 10.1055/s-0040-1716594
Review Article

Convalescent Plasma Therapy for COVID-19: Current Status and Future Directions

Jayanth Seshan
1   Department of Neuroanaesthesiology and Critical Care, Neurosciences Center, All India Institute of Medical Sciences, New Delhi, India
,
Surya K. Dube 
1   Department of Neuroanaesthesiology and Critical Care, Neurosciences Center, All India Institute of Medical Sciences, New Delhi, India
,
Vanitha Rajagopalan 
1   Department of Neuroanaesthesiology and Critical Care, Neurosciences Center, All India Institute of Medical Sciences, New Delhi, India
,
Pragyan S. Panda
2   Department of Microbiology, Janakpuri Super Speciality Hospital Society, Janakpuri, New Delhi, India
,
Girija P. Rath
1   Department of Neuroanaesthesiology and Critical Care, Neurosciences Center, All India Institute of Medical Sciences, New Delhi, India
› Institutsangaben
› Weitere Informationen
   Lizenzen und Reprints

Abstract

The ongoing pandemic of coronavirus disease 2019 (COVID-19) has triggered a global health crisis probably due to a lack of a reliable cure till date. Several clinical trials are ongoing, but initial results have not been overly promising. Convalescent plasma (CP), which refers to plasma collected from individuals recovered from an illness and developed antibodies against the pathogen, is also being proposed as a therapeutic option for COVID-19 treatment in severe cases to achieve short-term immunity against the virus. Use of CP is not new, and it has been used in various outbreaks over the past century, ranging from the Spanish influenza outbreak in 1918 to the recent Middle East respiratory syndrome (MERS). However, data available on its use in COVID-19 patients is limited. Use of CP so far is restricted to a “rescue therapy” and needs further trials to assess its possible use in other situations (prevention, postexposure prophylaxis) and patient populations (considering age and comorbid illnesses). In this review, we will try to summarize the current status of use of CP for COVID-19 and ongoing trials in India and elsewhere and will discuss the possible avenues for its use in future.

Keywords

convalescent plasma - coronavirus - COVID-19 - immunotherapy - SARS-CoV-2


Publikationsverlauf

Artikel online veröffentlicht:
16. Oktober 2020

© 2020. Indian Society of Neuroanaesthesiology and Critical Care. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223) 497-506
    CrossrefPubMedGoogle Scholar
  • 2 Vanamoorthy P, Singh GP, Bidkar PU. et al. The Neurocritical Care Society of India (NCSI) and the Indian Society of Neuroanaesthesiology and Critical Care (ISNACC) Joint Position Statement and Advisory on the Practice of Neurocritical Care during the COVID-19 Pandemic. J Neuroanaesth Crit Care 2020; 2: 49-114
    PubMedGoogle Scholar
  • 3 Li L, Zhang W, Hu Y. et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020; 324 (05) 1-11
    PubMedGoogle Scholar
  • 4 Ko JH, Seok H, Cho SY. et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther 2018; 23 (07) 617-622
    CrossrefPubMedGoogle Scholar
  • 5 Cheng Y, Wong R, Soo YO. et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24 (01) 44-46
    CrossrefPubMedGoogle Scholar
  • 6 Hung IF, To KK, Lee CK. et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52 (04) 447-456
    CrossrefPubMedGoogle Scholar
  • 7 Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007; 357 (14) 1450-1451
    CrossrefPubMedGoogle Scholar
  • 8 Sahr F, Ansumana R, Massaquoi TA. et al. Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone. J Infect 2017; 74 (03) 302-309
    CrossrefPubMedGoogle Scholar
  • 9 Ruggiero HA, Pérez Isquierdo F, Milani HA. et al. Treatment of Argentine hemorrhagic fever with convalescent’s plasma. 4433 cases [in French]. Presse Med 1986; 15 (45) 2239-2242
    PubMedGoogle Scholar
  • 10 Bloch EM, Shoham S, Casadevall A. et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020; 130 (06) 2757-2765
    CrossrefPubMedGoogle Scholar
  • 11 Duan K, Liu B, Li C. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020; 117 (17) 9490-9496
    CrossrefPubMedGoogle Scholar
  • 12 U.S. Food and Drug Administration. Recommendations for Investigational COVID-19 Convalescent Plasma. Available at: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma. Accessed April 29, 2020
  • 13 World Health Organization. Blood donor selection: guidelines on assessing donor suitability for blood donation. Available at: https://apps.who.int/iris/handle/10665/76724. Accessed June 5, 2020
  • 14 Marano G, Vaglio S, Pupella S. et al. Convalescent plasma: new evidence for an old therapeutic tool?. Blood Transfus 2016; 14 (02) 152-157
    Google Scholar
  • 15 Williams AE. FDA Considerations Regarding Frequent Plasma Collection Procedures. Available at: https://www.ihn-org.com/wp-content/uploads/2019/08/4-Williams FreqPlasma-2-21-131.pdf. Accessed June 5, 2020
  • 16 U.S. Food and Drug Administration. Compliance Policy Guide (CPG): CPG Sec. 252.110 Volume Limits for Automated Collection of Source Plasma (Obsolete, Withdrawn on 11/28/2017). Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-252110-volume-limits-automated-collection-source-plasma-obsolete-withdrawn-11282017. Accessed April 27, 2020
  • 17 Wong HK, Lee CK, Hung IFN. et al. Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection. Transfus (Paris) 2010; 50 (09) 1967-1971
    CrossrefPubMedGoogle Scholar
  • 18 Arabi YM, Hajeer AH, Luke T. et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis 2016; 22 (09) 1554-1561
    CrossrefPubMedGoogle Scholar
  • 19 Jh K, Ma MHS, Ge P. et al. Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity. Diagn Microbiol Infect Dis 2017; 89 (02) 106-111
    CrossrefPubMedGoogle Scholar
  • 20 Katzelnick LC, Gresh L, Halloran ME. et al. Antibody-dependent enhancement of severe dengue disease in humans. Science 2017; 358 (6365) 929-932
    CrossrefPubMedGoogle Scholar
  • 21 Shen C, Wang Z, Zhao F. et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020; 323 (16) 1582-1589
    CrossrefPubMedGoogle Scholar
  • 22 van Griensven J, Edwards T, de Lamballerie X. et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 2016; 374 (01) 33-42
    CrossrefPubMedGoogle Scholar
  • 23 World Health Organization. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease. Available at: https://www.who.int/csr/resources/publications/ebola/convalescent-treatment/en/. Accessed June 4, 2020
  • 24 Kong L. Severe acute respiratory syndrome (SARS). Transfus Apher Sci. 2003; 29 (01) 101
    CrossrefPubMedGoogle Scholar
  • 25 Johns Hopkins Medicine. Coronavirus COVID-19. Available at: https://www.hopkinsguides.com/hopkins/.//view/Johns_Hopkins_ABX_Guide/540747/all/Coronavirus_COVID_19__SARS_CoV_2?refer=true. Accessed April 27, 2020
  • 26 Soo YO, Cheng Y, Wong R. et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004; 10 (07) 676-678
    CrossrefPubMedGoogle Scholar
  • 27 Casadevall A, Joyner MJ, Pirofski LA. A randomized trial of convalescent plasma for COVID-19-potentially hopeful signals. JAMA 2020; DOI: 10.1001/jama.2020.10218.
    CrossrefPubMedGoogle Scholar
  • 28 Mair-Jenkins J, Saavedra-Campos M, Baillie JK. et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211 (01) 80-90
    CrossrefPubMedGoogle Scholar
  • 29 Chan KK, Lee KL, Lam PKN, Law KI, Joynt GM, Yan WW. Hong Kong’s experience on the use of extracorporeal membrane oxygenation for the treatment of influenza A (H1N1). Hong Kong Med J 2010; 16 (06) 447-454
    PubMedGoogle Scholar
  • 30 Chen N, Zhou M, Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395 (10223) 507-513
    CrossrefPubMedGoogle Scholar
  • 31 Hellstern P, Muntean W, Schramm W, Seifried E, Solheim BG. Practical guidelines for the clinical use of plasma. Thromb Res 2002; 107: S53-S57
    CrossrefPubMedGoogle Scholar
  • 32 Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?. Ann Intern Med 2006; 145 (08) 599-609
    CrossrefPubMedGoogle Scholar
  • 33 Mourya DT, Yadav PD, Majumdar TD, Chauhan DS, Katoch VM. Establishment of Biosafety Level-3 (BSL-3) laboratory: important criteria to consider while designing, constructing, commissioning & operating the facility in Indian setting. Indian J Med Res 2014; 140 (02) 171-183
    PubMedGoogle Scholar
  • 34 Valk SJ, Piechotta V, Chai KL. et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cochrane Database Syst Rev 2020; 5 (05) CD013600
    PubMedGoogle Scholar
  • 35 CTRI. A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Disease. Available at: http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=43149&EncHid=&userName=convalescent%20plasma. Accessed May 25, 2020
  • 36 Search Result, Clinical Trials Registry - India (CTRI) [Internet]. [cited 2020 May 25]. Available at: http://ctri.nic.in/Clinicaltrials/pubview2.php. Accessed May 25, 2020
  • 37 National COVID-19 Convalescent Plasma Project. Component 3: Clinical Trials. Available at: https://ccpp19.org/healthcare_providers/component_3/index.html. Accessed May 25, 2020
  • 38 Zhang B, Liu S, Tan T. et al. Treatment with convalescent plasma for critically Ill patients with SARS-CoV-2 infection. Chest 2020; 158 (01) e9-e13
    CrossrefPubMedGoogle Scholar
  • 39 Yeh KM, Chiueh TS, Siu LK. et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother 2005; 56 (05) 919-922
    CrossrefPubMedGoogle Scholar